Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study, incl. discussion and Q&A - Vienna 2024

From the editors' desk

Chair(s): Refika Hamutcu Ersu, Darren Taichman, James D. Chalmers

Session type: Journal session

Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study, incl. discussion and Q&A

Pamela J. McShane

EVENTS HOME

Replay
Slides

Previous presentation

Next presentation

Session content

Long-term oxygen therapy for 24 or 15 hours/day in severe hypoxemia, incl. discussion and Q&A

Magnus Ekstr?m

Replay

Slides

MK-5475, an inhaled soluble guanylate cyclase stimulator, for the treatment of pulmonary arterial hypertension, incl. discussion and Q&A

Marc Humbert

Replay

Slides

Tirzepatide for the treatment of obstructive sleep apnea and obesity, incl. discussion and Q&A

Atul Malhotra

Replay

Slides

Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study, incl. discussion and Q&A

Pamela J. Mcshane

Replay

Slides

Session aims

To discuss the latest high impact published data from the ERJ and the NEJM. We will present 4 recently published/accepted papers covering diverse topics in respiratory medicine

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}